Literature DB >> 11972068

Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L.

Jörg Stypmann1, Kerstin Gläser, Wera Roth, Desmond J Tobin, Ivonne Petermann, Rainer Matthias, Gerold Mönnig, Wilhelm Haverkamp, Günter Breithardt, Wolfgang Schmahl, Christoph Peters, Thomas Reinheckel.   

Abstract

Dilated cardiomyopathy is a frequent cause of heart failure and is associated with high mortality. Progressive remodeling of the myocardium leads to increased dimensions of heart chambers. The role of intracellular proteolysis in the progressive remodeling that underlies dilated cardiomyopathy has not received much attention yet. Here, we report that the lysosomal cysteine peptidase cathepsin L (CTSL) is critical for cardiac morphology and function. One-year-old CTSL-deficient mice show significant ventricular and atrial enlargement that is associated with a comparatively small increase in relative heart weight. Interstitial fibrosis and pleomorphic nuclei were found in the myocardium of the knockout mice. By electron microscopy, CTSL-deficient cardiomyocytes contained multiple large and apparently fused lysosomes characterized by storage of electron-dense heterogeneous material. Accordingly, the assessment of left ventricular function by echocardiography revealed severely impaired myocardial contraction in the CTSL-deficient mice. In addition, echocardiographic and electrocardiographic findings to some degree point to left ventricular hypertrophy that most likely represents an adaptive response to cardiac impairment. The histomorphological and functional alterations of CTSL-deficient hearts result in valve insufficiencies. Furthermore, abnormal heart rhythms, like supraventricular tachycardia, ventricular extrasystoles, and first-degree atrioventricular block, were detected in the CTSL-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972068      PMCID: PMC122932          DOI: 10.1073/pnas.092637699

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

Review 1.  The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms.

Authors:  J G Seidman; C Seidman
Journal:  Cell       Date:  2001-02-23       Impact factor: 41.582

2.  Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice.

Authors:  M C Colbert; D G Hall; T R Kimball; S A Witt; J N Lorenz; M L Kirby; T E Hewett; R Klevitsky; J Robbins
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

3.  Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.

Authors:  T Kubota; C F McTiernan; C S Frye; S E Slawson; B H Lemster; A P Koretsky; A J Demetris; A M Feldman
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

4.  MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure.

Authors:  S Arber; J J Hunter; J Ross; M Hongo; G Sansig; J Borg; J C Perriard; K R Chien; P Caroni
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 5.  Emerging roles for cysteine proteases in human biology.

Authors:  H A Chapman; R J Riese; G P Shi
Journal:  Annu Rev Physiol       Date:  1997       Impact factor: 19.318

6.  Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.

Authors:  M Kamisago; S D Sharma; S R DePalma; S Solomon; P Sharma; B McDonough; L Smoot; M P Mullen; P K Woolf; E D Wigle; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

Review 7.  Vacuolar/lysosomal proteolysis: proteases, substrates, mechanisms.

Authors:  M Knop; H H Schiffer; S Rupp; D H Wolf
Journal:  Curr Opin Cell Biol       Date:  1993-12       Impact factor: 8.382

8.  Accuracy of echocardiographic estimates of left ventricular mass in mice.

Authors:  K A Collins; C E Korcarz; S G Shroff; J E Bednarz; R C Fentzke; H Lin; J M Leiden; R M Lang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-05       Impact factor: 4.733

Review 9.  Metabolic cardiomyopathies.

Authors:  B Guertl; C Noehammer; G Hoefler
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

10.  Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy.

Authors:  R Coral-Vazquez; R D Cohn; S A Moore; J A Hill; R M Weiss; R L Davisson; V Straub; R Barresi; D Bansal; R F Hrstka; R Williamson; K P Campbell
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

View more
  50 in total

1.  Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth: a study with cathepsin-L-deficient mice.

Authors:  Fusanori Nishimura; Hisa Naruishi; Koji Naruishi; Teruo Yamada; Junzo Sasaki; Christoph Peters; Yasuo Uchiyama; Yoji Murayama
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

Review 3.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

Review 4.  Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.

Authors:  Vivian Hook; Lydiane Funkelstein; Douglas Lu; Steven Bark; Jill Wegrzyn; Shin-Rong Hwang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  From furless to heartless-unraveling the diverse functions of cathepsin L.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2009-01-25       Impact factor: 4.599

6.  Genes and environment: novel, functional polymorphism in the human cathepsin L (CTSL1) promoter disrupts a xenobiotic response element (XRE) to alter transcription and blood pressure.

Authors:  Nzali Mbewe-Campbell; Zhiyun Wei; Kuixing Zhang; Ryan S Friese; Manjula Mahata; Andrew J Schork; Fangwen Rao; Stephane Chiron; Nilima Biswas; Hyung-Suk Kim; Sushil K Mahata; Jill Waalen; Caroline M Nievergelt; Vivian Y Hook; Daniel T O'Connor
Journal:  J Hypertens       Date:  2012-10       Impact factor: 4.844

Review 7.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 8.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

9.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter.

Authors:  Sukkid Yasothornsrikul; Doron Greenbaum; Katalin F Medzihradszky; Thomas Toneff; Richard Bundey; Ruthellen Miller; Birgit Schilling; Ivonne Petermann; Jessica Dehnert; Anna Logvinova; Paul Goldsmith; John M Neveu; William S Lane; Bradford Gibson; Thomas Reinheckel; Christoph Peters; Matthew Bogyo; Vivian Hook
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.